Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

被引：16

作者：

Modi, S. ^{[1
]}

Jacot, W. ^{[2
]}

Iwata, H. ^{[3
]}

Park, Y. H. ^{[4
]}

Vidal Losada, M. J. ^{[5
]}

Li, W. ^{[6
]}

Tsurutani, J. ^{[7
]}

Zaman, K. ^{[8
]}

Ueno, N. T. ^{[9
]}

Prat, A. ^{[10
]}

Papazisis, K. ^{[11
]}

Rugo, H. S. ^{[12
]}

Harbeck, N. ^{[13
]}

Im, S-A. ^{[14
]}

De Laurentiis, M. ^{[15
]}

Orbegoso, C. M. A. ^{[16
]}

Yung, L. ^{[17
]}

Cheng, F-C. ^{[18
]}

Cheng, Y. ^{[19
]}

Cameron, D. A. ^{[20
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA

[2] Inst Canc Montpellier, Med Oncol, Montpellier, France

[3] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan

[4] Samsung Med Ctr, Hematol Oncol, Seoul, South Korea

[5] Hosp Clin Barcelona, Oncol Med, Barcelona, Spain

[6] First Hosp Jilin Univ, Tumor Ctr, Changchun, Jilin, Peoples R China

[7] Showa Univ, Adv Canc Translat Res Inst, Shinagawa, Japan

[8] Lausanne Univ Hosp CHUV, Oncol, Lausanne, Switzerland

[9] Univ Hawaii, Med, Ctr Canc, Honolulu, HI USA

[10] August Pi & Sunyer Biomed Res Inst IDIBAPS, Med Oncol, Translat Genom & Targeted Therapies Grp, Barcelona, Spain

[11] Euromed Gen Clin, Oncol, Thessaloniki, Greece

[12] UCSF, Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[13] LMU Univ Hosp, Breast Ctr, Obstet & Gynecol, Munich, Germany

[14] Seoul Natl Univ, Seoul Natl Univ Hosp, Internal Med, Coll Med, Seoul, South Korea

[15] Ist Nazl Tumori IRCCS Fdn G Pascale, Breast Oncol Unit, Naples, Italy

[16] Daiichi Sankyo Inc, Global Oncol Res & Dev, Rueil Malmaison, France

[17] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA

[18] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA

[19] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA

[20] Univ Edinburgh, Edinburgh Univ Canc Ctr, Edinburgh, Midlothian, Scotland

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.553

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

376O

引用

页码：S334 / S335

页数：2

共 50 条

[31] Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03
Saura, Cristina
Cortes, Javier
Modi, Shanu
Kim, Sung-Bae
Hamilton, Erika P.
Hurvitz, Sara A.
Krop, Ian E.
Curigliano, Giuseppe
Iwata, Hiroji
Im, Seock-Ah
Herbolsheimer, Pia Maarit
Karnoub, Maha
Gambhire, Dhiraj
Egorov, Anton
Andre, Fabrice
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[32] Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)
Cortes, J.
Im, S-A.
Iwata, H.
Hamilton, E. P.
Hurvitz, S. A.
Egorov, A.
Cathcart, J.
Liu, Y.
Bako, E.
Curigliano, G.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S645 - S646
[33] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results
Lin, N.
Ciruelos, E. M.
Jerusalem, G.
Mueller, V.
Niikura, N.
Viale, G.
Bartsch, R.
Kurzeder, C.
Connolly, R.
Baron-Hay, S. E.
Cortes, M. Gion
Guarneri, V.
Bianchini, G.
Wildiers, H.
Escriva-de-Romani, S.
Prahladan, M.
Bridge, H.
Verma, S.
Harbeck, N.
ANNALS OF ONCOLOGY, 2024, 35 : 1211 - 1212
[34] ALTER-BC-Ib-01: A prospective phase Ib study of anlotinib with trastuzumab deruxtecan (T-DXd) for HER2-low unresectable (u)/metastatic (m) breast cancer (BC)
Meng, Y.
Mu, Y.
Zhang, J.
ANNALS OF ONCOLOGY, 2024, 35 : S402 - S402
[35] Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
Hurvitz, Sara
Kim, Sung-Bae
Chung, Wei-Pang
Im, Seock-Ah
Park, Yeon Hee
Hegg, Roberto
Kim, Min-Hwan
Tseng, Ling-Ming
Petry, Vanessa
Chung, Chi-Feng
Iwata, Hiroji
Hamilton, Erika
Curigliano, Giuseppe
Xu, Binghe
Lee, Caleb
Liu, Yali
Cathcart, Jillian
Bako, Emarjola
Verma, Sunil
Cortes, Javier
CANCER RESEARCH, 2022, 82 (04)
[36] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
Powell, C. A.
Modi, S.
Iwata, H.
Takahashi, S.
Nie, K.
Qin, A.
Singh, J.
Taitt, C.
Verma, S.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
[37] An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03
Krop, Ian E.
Wildiers, Hans
Hurvitz, Sara A.
Cortes, Javier
Im, Seock-Ah
Iwata, Hiroji
Andre, Fabrice
Saura, Cristina
Modi, Shanu
Kim, Sung-Bae
Egorov, Anton
Mathias, Elton
Cathcart, Jillian
Cagnazzo, Antonio
Cheng, Yingkai
Park, Yeon Hee
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[38] A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
O'Shaughnessy, Joyce
Basho, Reva
Lustberg, Maryam
Lyman, Gary H.
Prahladan, Manoj
James, Gareth D.
Varghese, Della
Lujan, Flavia
Tesch, Hans
CANCER RESEARCH, 2024, 84 (09)
[39] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
Jerusalem, Guy Heinrich Maria
Park, Yeon Hee
Yamashita, Toshinari
Hurvitz, Sara A.
Modi, Shanu
Andre, Fabrice
Krop, Ian E.
Gonzalez, Xavier
Hall, Peter S.
You, Benoit
Saura, Cristina
Kim, Sung-Bae
Osborne, Cynthia R. C.
Sagara, Yasuaki
Tokunaga, Eriko
Liu, Yali
Cathcart, Jillian
Lee, Caleb C.
Perrin, Christophe
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[40] A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03
Hurvitz, S. A.
Modi, S.
Li, W.
Park, Y. H.
Chung, W.
Kim, S-B.
Cortes, J.
Yamashita, T.
Pedrini, J.
Im, S-A.
Tseng, L-M.
Harbeck, N.
Krop, I.
Curigliano, G.
Mathias, E.
Cathcart, J.
Cagnazzo, A.
Ashfaque, S.
Egorov, A.
Andre, F.
ANNALS OF ONCOLOGY, 2023, 34 : S335 - S336

← 1 2 3 4 5 →